February 2019 Issue Table Of Contents
Source: Life Science Leader

From The Editor
Feature Articles
Capitol Perspectives
Patient Perspectives
CEO Corner
- Considerations For Effective International Collaborations
- Lessons Learned: The Start Of mRNA Technology Development
From Principles and Policy to Execution
Companies To Watch
Industry Research
Inside The Industry
- How Will mHealth Benefit Clinical Trials?
- BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing
- Foreign Investors Trigger ‘Critical Technology’ Review for Biotech
- Combatting Unproven Cell And Gene Therapies Through Regulation And Education
- Why Patent Protection Is Key To Commercializing Repurposed Drugs
- Digital Ledger Technologies Supporting Regulatory Exchange
- Maturity Assessment – The First Step Of The Pharma 4.0 Journey
- Why 2018 Was The Year Of Real-World Evidence For Biosimilars
- Master Trial Protocols: Better For Pharma, Better For Sites
- The Drug-Delivery Company That Partnerships Built
- Beyond The Printed Page Highlights
Industry Leader
Leadership Lessons
Ask The Board
- Should We Be Thinking About The Ethical Considerations Of Approving Clinical Trials Based On Scientific Merit/Patient Safety When 30 Percent Of Trials Will Never Complete Enrollment? Are We Breaking Our Commitment To Patients?
- When Do You Think Clinical Research Will Be A True Integral Option Within The Continual Care Of Patients, And What Do You See Will Help Drive It There?
- Virtual Clinical Trials Are Here. Do You Think The Pharma And Medical Industries Are Ready?
This website uses cookies to ensure you get the best experience on our website. Learn more